LataMed AI Corp. (OTC: LMED) announced that its mobile healthcare application has entered the final development stage, with the company completing testing and optimization before submission to the Apple App Store and Google Play. The app, expected to become available in the coming weeks pending platform review, will serve as a primary mobile gateway to LataMed AI's digital healthcare ecosystem, offering users a convenient interface to access supported services and tools.
This milestone is strategically significant for LataMed AI, which focuses on Latin America, where smartphones are often the primary means of accessing digital services. By launching on both major app stores, the company aims to provide a direct and accessible entry point for users, while establishing a scalable mobile infrastructure for future enhancements. Potential features include patient-facing tools, healthcare-provider interaction, digital communications, medical information, and service coordination, all designed to foster a more connected healthcare experience.
The app's release also aligns with LataMed AI's longer-term vision of integrating patients, healthcare professionals, pharmacies, insurers, payment providers, and wellness organizations into a unified digital health environment. The company continues to develop its AI-supported technologies, including CardioAI, PulmoAI, and NeuroAI, which are intended to assist healthcare professionals in cardiovascular, pulmonary, and neurological evaluations. The mobile platform is expected to provide an additional pathway for users and professionals to interact with these components, subject to ongoing development and regulatory compliance.
Dr. Kevin Rodan Levy, CEO of LataMed AI, emphasized the importance of mobile accessibility: "Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building. Our objective is to create a platform that is practical, accessible, and capable of expanding as we continue introducing additional healthcare services and artificial intelligence-supported tools."
The company's development team is currently focused on final technical testing, interface optimization, and platform compatibility checks. Following the initial release, LataMed AI plans to evaluate additional functionality and integrations for future versions. The company expects to provide updates as submission and availability milestones are completed.
The move from development to deployment marks a critical transition for LataMed AI, which has been building its digital health infrastructure. With the app's launch, the company will be closer to achieving its goal of making healthcare services more accessible to underserved populations in Latin America. However, the success of the app will depend on user adoption, platform approval, and the ability to scale the ecosystem effectively.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
